Payment overview · 2025
General Payments
$250.48
12 reported records · 6 companies
Healthcare provider profile · identity verified
William Gerry Hebert, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LAKE CHARLES, LA · NPI 1598834491
Verified facts
What the public records show
CMS Open Payments records show William Gerry Hebert, M.D. received $250.48 in general payments during 2025 across 12 reported records.
PFIZER INC. accounted for 34.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.76 | 34.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.66 | 23.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.48 | 22.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.30 | 7.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.98 | 7.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.30 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $250.48 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $85.76 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $57.48 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.48 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.37 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 160 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
113 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
160 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 564 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 448 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 382 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 334 | 75 |
| Lisinopril | Lisinopril | 304 | 81 |
| Gabapentin | Gabapentin | 294 | 54 |
| Trazodone Hcl | Trazodone Hcl | 287 | 64 |
| Citalopram Hbr | Citalopram Hydrobromide | 286 | 51 |
| Januvia | Sitagliptin Phosphate | 243 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 213 | 51 |
| Montelukast Sodium | Montelukast Sodium | 204 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 197 | 49 |
| Furosemide | Furosemide | 196 | 40 |
| Metformin Hcl | Metformin Hcl | 191 | 51 |
| Donepezil Hcl | Donepezil Hcl | 184 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 40 |
| Sertraline Hcl | Sertraline Hcl | 168 | 39 |
| Eliquis | Apixaban | 160 | 22 |
| Losartan Potassium | Losartan Potassium | 160 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 159 | 36 |
| Meloxicam | Meloxicam | 153 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 35 |
| Omeprazole | Omeprazole | 151 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 137 | 32 |
| Potassium Chloride | Potassium Chloride | 133 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 40 |
| Alprazolam | Alprazolam | 118 | 21 |
| Jardiance | Empagliflozin | 113 | 18 |
| Memantine Hcl | Memantine Hcl | 111 | 21 |
| Tramadol Hcl | Tramadol Hcl | 107 | 24 |
| Valsartan | Valsartan | 106 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 99 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 99 | 19 |
| Allopurinol | Allopurinol | 97 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 78 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 12 |
| Buspirone Hcl | Buspirone Hcl | 73 | 15 |
| Alendronate Sodium | Alendronate Sodium | 70 | 23 |
| Clonazepam | Clonazepam | 70 | 16 |
| Bupropion Xl | Bupropion Hcl | 69 | 13 |
| Mirtazapine | Mirtazapine | 68 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 68 | 51 |
| Solifenacin Succinate | Solifenacin Succinate | 65 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 62 | 11 |
| Ezetimibe | Ezetimibe | 60 | 17 |
| Synthroid | Levothyroxine Sodium | 58 | 20 |
| Celecoxib | Celecoxib | 57 | 18 |
| Pregabalin | Pregabalin | 57 | suppressed |
| Lorazepam | Lorazepam | 56 | suppressed |
| Carvedilol | Carvedilol | 54 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 53 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 52 | 15 |
| Temazepam | Temazepam | 52 | 13 |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 11 |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Sucralfate | Sucralfate | 48 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 12 |
| Prednisone | Prednisone | 45 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Ondansetron Odt | Ondansetron | 42 | suppressed |
| Simvastatin | Simvastatin | 42 | suppressed |
| Glimepiride | Glimepiride | 41 | 11 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 39 | suppressed |
| Azithromycin | Azithromycin | 38 | 30 |
| Cefdinir | Cefdinir | 37 | 27 |
| Finasteride | Finasteride | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Nystatin | Nystatin | 26 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Testosterone | Testosterone | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Diazepam | Diazepam | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 19 |
| Levofloxacin | Levofloxacin | 20 | 18 |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | 11 |
| Glipizide | Glipizide | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Lovastatin | Lovastatin | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Chlordiazepoxide-Clidinium | Chlordiazepoxide/Clidinium Br | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $250.48 · 12 records | PFIZER INC. | AREXVY, CREON, ELIQUIS, LINZESS, MOUNJARO, QULIPTA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error